Reporting
CTN 254: Inflammation as a predictor of HIV disease progression
Predictive value of inflammatory biomarkers in untreated HIV disease progression, and their response to initiation of antiretroviral therapy
Learn MoreReporting
Predictive value of inflammatory biomarkers in untreated HIV disease progression, and their response to initiation of antiretroviral therapy
Learn MoreCompleted
PCIRN evaluation of pandemic H1N1 (2009) influenza vaccine in adults with human immunodeficiency virus infection: Trial results
Learn MoreReporting
A randomized clinical trial evaluating the role of contingent reinforcement in the engagement and retention of Drug Users in HAART programs: a substudy of CTN 244
Learn MoreReporting
A study of host and viral factors associated with disease progression in long term HIV infected subjects
Learn MoreCompleted
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
Learn MoreCompleted
Seek and Treat for Optimal outcomes and Prevention in HIV& AIDS in IDU
Learn MoreCompleted
Please Note: This is an observational study and is designed to examine and link HIV/AIDS information drawn from databases across Canada
Learn MoreCompleted
Valacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
Learn MoreCompleted
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
Learn MoreCTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.